CUREVAC NV (5CV.DE) Stock Fundamental Analysis
Europe • Frankfurt Stock Exchange • FRA:5CV • NL0015436031
3.892 EUR
+0.01 (+0.36%)
Last: Jan 5, 2026, 07:00 PM
5CV gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 85 industry peers in the Biotechnology industry. 5CV has an average financial health and profitability rating. 5CV does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- 5CV had negative earnings in the past year.
- 5CV had a negative operating cash flow in the past year.
- In the past 5 years 5CV reported 4 times negative net income.
- The reported operating cash flow has been mixed in the past 5 years: 5CV reported negative operating cash flow in multiple years.
1.2 Ratios
- The Return On Assets of 5CV (11.31%) is better than 84.34% of its industry peers.
- 5CV has a better Return On Equity (14.79%) than 84.34% of its industry peers.
- 5CV has a better Return On Invested Capital (14.12%) than 87.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| ROIC | 14.12% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- 5CV's Profit Margin of 182.11% is amongst the best of the industry. 5CV outperforms 98.80% of its industry peers.
- 5CV has a better Operating Margin (212.01%) than 98.80% of its industry peers.
- Looking at the Gross Margin, with a value of 93.01%, 5CV belongs to the top of the industry, outperforming 86.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 212.01% | ||
| PM (TTM) | 182.11% | ||
| GM | 93.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 5CV is creating value.
- The number of shares outstanding for 5CV remains at a similar level compared to 1 year ago.
- Compared to 5 years ago, 5CV has more shares outstanding
- Compared to 1 year ago, 5CV has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 4.17 indicates that 5CV is not in any danger for bankruptcy at the moment.
- 5CV has a better Altman-Z score (4.17) than 73.49% of its industry peers.
- A Debt/Equity ratio of 0.03 indicates that 5CV is not too dependend on debt financing.
- With a decent Debt to Equity ratio value of 0.03, 5CV is doing good in the industry, outperforming 69.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.17 |
ROIC/WACC1.96
WACC7.19%
2.3 Liquidity
- A Current Ratio of 3.70 indicates that 5CV has no problem at all paying its short term obligations.
- 5CV's Current ratio of 3.70 is fine compared to the rest of the industry. 5CV outperforms 69.88% of its industry peers.
- A Quick Ratio of 3.69 indicates that 5CV has no problem at all paying its short term obligations.
- The Quick ratio of 5CV (3.69) is better than 73.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.7 | ||
| Quick Ratio | 3.69 |
3. Growth
3.1 Past
- The earnings per share for 5CV have decreased strongly by -247.92% in the last year.
- Looking at the last year, 5CV shows a very negative growth in Revenue. The Revenue has decreased by -86.98% in the last year.
- Measured over the past years, 5CV shows a very strong growth in Revenue. The Revenue has been growing by 98.42% on average per year.
EPS 1Y (TTM)-247.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.33%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%
3.2 Future
- The Earnings Per Share is expected to decrease by -22.50% on average over the next years. This is quite bad
- Based on estimates for the next years, 5CV will show a very negative growth in Revenue. The Revenue will decrease by -11.14% on average per year.
EPS Next Y-163.99%
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue Next Year-84.14%
Revenue Next 2Y-55.71%
Revenue Next 3Y-30.85%
Revenue Next 5Y-11.14%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for 5CV. In the last year negative earnings were reported.
- Also next year 5CV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, 5CV is valued cheaply inside the industry as 96.39% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 2.92 |
4.3 Compensation for Growth
- A cheap valuation may be justified as 5CV's earnings are expected to decrease with -28.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
5. Dividend
5.1 Amount
- No dividends for 5CV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CUREVAC NV / 5CV.DE FAQ
Can you provide the ChartMill fundamental rating for CUREVAC NV?
ChartMill assigns a fundamental rating of 4 / 10 to 5CV.DE.
What is the valuation status of CUREVAC NV (5CV.DE) stock?
ChartMill assigns a valuation rating of 3 / 10 to CUREVAC NV (5CV.DE). This can be considered as Overvalued.
Can you provide the profitability details for CUREVAC NV?
CUREVAC NV (5CV.DE) has a profitability rating of 5 / 10.
What is the financial health of CUREVAC NV (5CV.DE) stock?
The financial health rating of CUREVAC NV (5CV.DE) is 6 / 10.